Biotie Reaches Wyeth Milestone

Biotie has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a $1.0 million milestone payment to Biotie.

Timo Veromaa, president and chief executive officer of Biotie, said, “We are pleased with the progress we have made in collaboration with Wyeth on the PDE10 inhibitor program and look forward to beginning our work together in the clinic. We believe this partnership provides further validation for our PDE platform technology, which has already provided us with one active clinical program and several pre-clinical programs.”

PDE10 is a novel CNS drug target that is thought to play an important role in the pathophysiology of schizophrenia. Biotie has demonstrated that inhibitors of PDE10 display antipsychotic activity in experimental models, indicating the potential for a superior efficacy and tolerability profile versus current standard therapies.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference